HHS makes finding addiction treatment easier with FindTreatment.gov
The portal has data from 13,000 addiction treatment centers.
Government
FDA after Gottlieb: Sharpless expected to push predecessor’s agenda during transition
The Senate may not take up a confirmation vote before the 2020 election, but one Beltway insider predicts the FDA will still be potent during the transition to a new commissioner.
Reports: Gottlieb to resign from FDA
Gottlieb has served in the FDA’s top job since April 2017.
4 healthcare things to know about the new federal budget
#1: The FDA is getting its biggest funding increase since 2010.
Gilead names Michael Boyd VP of government affairs, policy
Boyd has worked at AbbVie, Pfizer, and Schering-Plough.
4 expert takes on what the midterms mean for pharma
MM&M asked experts to predict what the next two years could hold for pharma- and healthcare-related legislation.
Five things for pharma marketers to know: Monday, January 22, 2018
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
NORML balances federal, local action after Cole memo reversal
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
From working for one administration to fending off another: Planned Parenthood’s Kevin Griffis
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
Five things for pharma marketers to know: Wednesday, January 3, 2018
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark’s genetic therapy for rare blindness costs $850,000
